Wren Laboratories

What Wren Laboratories does

Wren Laboratories is a privately held molecular diagnostics laboratory headquartered in Branford, Connecticut, founded in 2014. The company develops and offers liquid biopsy mRNA-based diagnostic tests focused on neuroendocrine cancers, prostate cancer, and Covid-19, indicating specialization in non-invasive, blood-based molecular testing across both oncology and infectious disease indications. Its test menu positions it in the clinical reference laboratory segment of the molecular diagnostics industry, where assays are typically ordered by specialist physicians and processed centrally.

Operating with an estimated 11-50 employees, Wren Laboratories occupies a niche position in the clinical diagnostics value chain, most likely serving clinicians — including oncologists, urologists, and infectious disease specialists — and the patients they refer for specialized molecular testing. Its business model appears consistent with that of a specialty reference laboratory: tests are ordered by physicians, processed at the lab, and reimbursed through a mix of insurance, hospital billing, and direct-pay channels. No specific pricing, customer segmentation, go-to-market motion, or revenue mechanics are disclosed in the available source material, and the company's own web presence (as captured in the source scrape) returned only a verification interstitial with no product or operational content.

The company's competitive context — operating in molecular diagnostics adjacent to larger reference labs with broader test menus and deeper commercial reach — implies its differentiation rests on assay specialization in niche indications (notably neuroendocrine tumors) where larger incumbents may have thinner coverage. However, the available source data is materially limited: no funding history, management team details, customer logos, certifications, partnerships, product-level pricing, technology stack, or AI capability information is disclosed, which constrains any deeper assessment of scale, unit economics, or defensibility.

Name

Wren Laboratories

Website

https://wrenlaboratories.com

Company type

Private

Founded year

2013

Headcount range

11–50 employees

Short description

Wren Laboratories is a privately held molecular diagnostics laboratory in Branford, Connecticut, founded in 2014, offering liquid biopsy mRNA-based tests for neuroendocrine cancer, prostate cancer, and Covid-19 to clinicians and patients.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Reference & Esoteric Testing Laboratories (HLAFAMAJ)

Keywords

• Molecular diagnostics
• Liquid biopsy tests
• Cancer diagnostics
• MRNA testing
• Clinical laboratory services

Headquarters

HQ city

Branford

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Core offering

Wren Laboratories is a molecular diagnostics laboratory that performs liquid biopsy mRNA tests for the detection and monitoring of neuroendocrine cancer, prostate cancer, and Covid-19. The laboratory provides blood-based diagnostic testing services using proprietary mRNA gene expression analysis to support clinicians in non-invasive tumor characterization and infectious disease detection.

Product overview

Based on the available source data, there is insufficient information to provide a detailed product overview for Wren Laboratories. The scraped webpage content shows only a verification loading page with no product, service, or company information. No product names, descriptions, or portfolio details could be extracted from the provided sources.

Differentiator

Problem solved

Functional benefit

Products and services

• Neuroendocrine Cancer Liquid Biopsy mRNA Test
• Prostate Cancer Liquid Biopsy mRNA Test
• Covid-19 Liquid Biopsy mRNA Test

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves2 records

Expansion highlights2 records

Broad incumbents

• Exact Sciences: Cancer screening and diagnostics company with multiple liquid- and stool-based assays. Comparable molecular diagnostics commercial model, though much larger and focused on screening populations rather than specialty oncology.
• Foundation Medicine: Molecular profiling company (Roche subsidiary) offering comprehensive genomic profiling of tumors. Comparable specialty molecular diagnostics model with deep pharma and clinical trial services exposure, at much greater scale.
• NeoGenomics: Specialty oncology-focused clinical laboratory providing molecular and other diagnostic services to community hospitals and oncologists. Closely comparable customer base and specialty oncology focus, but at public-company scale.
• Guardant Health: Leading commercial liquid biopsy company offering blood-based ctDNA assays across multiple cancer types. Direct overlap with Wren's liquid biopsy approach, but operates at significantly larger scale with broad pan-cancer indications.
• Quest Diagnostics: National clinical reference laboratory offering a broad menu of molecular and esoteric tests, including oncology. Competes in the same hospital/oncology channel as Wren but with national scale and broad payer relationships.
• Natera: Molecular diagnostics company with oncology and organ-health liquid biopsy tests. Comparable technology platform and customer base (oncologists, hospitals), but at a much larger commercial scale.

Direct peers

• Caris Life Sciences: Specialty molecular profiling lab combining DNA, RNA, and protein biomarker readouts for cancer. Closely comparable to Wren on technology (multi-analyte molecular profiling) and on the specialty reference lab model.
• Tempus: AI-enabled precision medicine company offering multi-omic molecular profiling and clinical decision support for oncology. Closely comparable on molecular profiling for cancer, with overlap on biomarker-based clinical trial services.

Emerging players

• Personalis: Specialty molecular diagnostics company focused on cancer genomics with an emphasis on immuno-oncology biomarkers. Comparable technology approach (specialty tumor molecular profiling), though more focused on pharma/biopharma trial services.

Others

• Bio-Techne: Life sciences tools company supplying reagents, antibodies, and assay components used in specialty molecular diagnostics labs. Adjacent rather than directly competing — could be a supplier/partner to Wren rather than a competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/wrenlabs
• Facebookfacebook.com/WrenLaboratories
• LinkedInlinkedin.com/company/wren-laboratories

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wren Laboratories